HAMBURG, Germany and OXFORD, England, September 24 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that Jorn Aldag, President & CEO, and Dr John Kemp, Chief Research & Development Officer, will present at the UBS 2007 Global Life Sciences Conference at 03.30 pm EST (09.30 pm CET/08.30 pm BST) on Wednesday, 26 September 2007, at Grand Hyatt, New York City. During the presentation management will provide an overview of its recently announced agreement to acquire Renovis, Inc.
The company presentation will be webcast live and will be accessible through the Evotec website at http://www.evotec.com - Investors. A replay will also be available at http://www.evotec.com - Investors - Webcasts.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.
In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.
Forward looking statements
Information set forth in this communication contains forward-looking
statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to, statements
about the anticipated benefits of Evotec's p
|SOURCE Evotec AG|
Copyright©2007 PR Newswire.
All rights reserved